Direct interactions with both p27 and Cdk2 regulate Spy1-mediated proliferation in vivo and in vitro

References

• De Bondt HL, Rosenblatt J, Jancarik J, Jones HD, Morgan DO, Kim SH. Crystal structure of cyclin-dependent kinase 2. Nature 1993; 363:595–602; PMID:8510751; http://dx.doi.org/10.1038/363595a0
   PubMed Web of Science ®Google Scholar
• Nurse PM. Nobel Lecture. Cyclin dependent kinases and cell cycle control. Biosci Rep 2002; 22:487-99; PMID:12635846; http://dx.doi.org/10.1023/A:1022017701871
   PubMed Web of Science ®Google Scholar
• Said TK, Medina D. Cell cyclins and cyclin-dependent kinase activities in mouse mammary tumor development. Carcinogenesis 1995; 16:823-30; PMID:7728962; http://dx.doi.org/10.1093/carcin/16.4.823
   PubMed Web of Science ®Google Scholar
• Alkarain A, Jordan R, Slingerland J. p27 deregulation in breast cancer: prognostic significance and implications for therapy. J Mammary Gland Biol Neoplasia 2004; 9:67-80; PMID:15082919; http://dx.doi.org/10.1023/B:JOMG.0000023589.00994.5e
   PubMed Web of Science ®Google Scholar
• Nair BC, Vallabhaneni S, Tekmal RR, Vadlamudi RK. Roscovitine confers tumor suppressive effect on therapy-resistant breast tumor cells. Breast Cancer Res 2011; 13: R80; PMID:21834972; http://dx.doi.org/10.1186/bcr2929
   PubMed Web of Science ®Google Scholar
• Appleyard MV, O'Neill MA, Murray KE, Paulin FE, Bray SE, Kernohan NM, Levison DA, Lane DP, Thompson AM. Seliciclib (CYC202, R-roscovitine) enhances the antitumor effect of doxorubicin in vivo in a breast cancer xenograft model. Int J Cancer 2009; 124:465-72; PMID:19003963; http://dx.doi.org/10.1002/ijc.23938
   PubMed Web of Science ®Google Scholar
• Dickson MA, Schwartz GK. Development of cell-cycle inhibitors for cancer therapy. Curr Oncol 2009; 16:36-43; PMID:19370178
   PubMed Web of Science ®Google Scholar
• Malumbres M, Pevarello P, Barbacid M, Bischoff JR. CDK inhibitors in cancer therapy: what is next? Trends Pharmacol Sci 2008; 29:16-21; PMID:18054800; http://dx.doi.org/10.1016/j.tips.2007.10.012
   PubMed Web of Science ®Google Scholar
• Guha M. Blockbuster dreams for Pfizer's CDK inhibitor. Nat Biotechnol 2013; 31:187; PMID:23471056; http://dx.doi.org/10.1038/nbt0313-187a
   PubMed Web of Science ®Google Scholar
• Porter LA, Dellinger RW, Tynan JA, Barnes EA, Kong M, Lenormand JL, Donoghue DJ. Human Speedy: a novel cell cycle regulator that enhances proliferation through activation of Cdk2. J Cell Biol 2002; 157:357-66; PMID:11980914; http://dx.doi.org/10.1083/jcb.200109045
   PubMed Web of Science ®Google Scholar
• Porter LA, Kong-Beltran M, Donoghue DJ. Spy1 interacts with p27Kip1 to allow G1/S progression. Mol Biol Cell 2003; 14:3664-74; PMID:12972555; http://dx.doi.org/10.1091/mbc.E02-12-0820
   PubMed Web of Science ®Google Scholar
• Cheng A, Gerry S, Kaldis P, Solomon MJ. Biochemical characterization of Cdk2-Speedy/Ringo A2 BMC Biochem 2005; 6:19; PMID:16191191; http://dx.doi.org/10.1186/1471-2091-6-19
   PubMedGoogle Scholar
• Barnes EA, Porter LA, Lenormand JL, Dellinger RW, Donoghue DJ. Human Spy1 promotes survival of mammalian cells following DNA damage. Cancer Res 2003; 63:3701-7; PMID:12839962
   PubMed Web of Science ®Google Scholar
• Gastwirt RF, Slavin DA, McAndrew CW, Donoghue DJ. Spy1 expression prevents normal cellular responses to DNA damage: inhibition of apoptosis and checkpoint activation. J Biol Chem 2006; 281:35425-35; PMID:16951407; http://dx.doi.org/10.1074/jbc.M604720200
   PubMed Web of Science ®Google Scholar
• McAndrew CW, Gastwirt RF, Meyer AN, Porter LA, Donoghue DJ. Spy1 enhances phosphorylation and degradation of the cell cycle inhibitor p27. Cell Cycle 2007; 6:1937-45; PMID:17671428; http://dx.doi.org/10.4161/cc.6.15.4520
   PubMed Web of Science ®Google Scholar
• Cheng A, Xiong W, Ferrell JE Jr., Solomon MJ. Identification and comparative analysis of multiple mammalian Speedy/Ringo proteins. Cell Cycle 2005; 4:155-65; PMID:15611625; http://dx.doi.org/10.4161/cc.4.1.1347
   PubMed Web of Science ®Google Scholar
• Golipour A, Myers D, Seagroves T, Murphy D, Evan GI, Donoghue DJ, Moorehead RA, Porter LA. The Spy1/RINGO family represents a novel mechanism regulating mammary growth and tumorigenesis. Cancer Res 2008; 68:3591-600; PMID:18483240; http://dx.doi.org/10.1158/0008-5472.CAN-07-6453
   PubMed Web of Science ®Google Scholar
• Al Sorkhy M, Ferraiuolo RM, Jalili E, Malysa A, Fratiloiu AR, Sloane BF, Porter LA. The cyclin-like protein Spy1/RINGO promotes mammary transformation and is elevated in human breast cancer. BMC Cancer 2012; 12:45; PMID:22280365; http://dx.doi.org/10.1186/1471-2407-12-45
   PubMed Web of Science ®Google Scholar
• Welm BE, Dijkgraaf GJ, Bledau AS, Welm AL, Werb Z. Lentiviral transduction of mammary stem cells for analysis of gene function during development and cancer. Cell Stem Cell 2008; 2:90-102; PMID:18371425; http://dx.doi.org/10.1016/j.stem.2007.10.002
   PubMedGoogle Scholar
• Al Sorkhy M, Craig R, Market B, Ard R, Porter LA. The cyclin-dependent kinase activator, Spy1A, is targeted for degradation by the ubiquitin ligase NEDD4. J Biol Chem 2009; 284:2617-27; PMID:19054764; http://dx.doi.org/10.1074/jbc.M804847200
   PubMed Web of Science ®Google Scholar
• Wang W, Ungermannova D, Chen L, Liu X. Molecular and biochemical characterization of the Skp2-Cks1 binding interface. J Biol Chem 2004; 279:51362-9; PMID:15452136; http://dx.doi.org/10.1074/jbc.M405944200
   PubMed Web of Science ®Google Scholar
• Ungermannova D, Gao Y, Liu X. Ubiquitination of p27Kip1 requires physical interaction with cyclin E and probable phosphate recognition by SKP2. J Biol Chem 2005; 280:30301-9; PMID:15980415; http://dx.doi.org/10.1074/jbc.M411103200
   PubMed Web of Science ®Google Scholar
• Sitry D, Seeliger MA, Ko TK, Ganoth D, Breward SE, Itzhaki LS, Pagano M, Hershko A. Three different binding sites of Cks1 are required for p27-ubiquitin ligation. J Biol Chem 2002; 277:42233-40; PMID:12140288; http://dx.doi.org/10.1074/jbc.M205254200
   PubMed Web of Science ®Google Scholar
• Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, Pagano M. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev 1999; 13:1181-9; PMID:10323868; http://dx.doi.org/10.1101/gad.13.9.1181
   PubMed Web of Science ®Google Scholar
• Zucchi I, Mento E, Kuznetsov VA, Scotti M, Valsecchi V, Simionati B, Vicinanza E, Valle G, Pilotti S, Reinbold R, et al. Gene expression profiles of epithelial cells microscopically isolated from a breast-invasive ductal carcinoma and a nodal metastasis. Proc Natl Acad Sci U S A 2004; 101:18147-52; PMID:15608061; http://dx.doi.org/10.1073/pnas.0408260101
   PubMed Web of Science ®Google Scholar
• Ke Q, Ji J, Cheng C, Zhang Y, Lu M, Wang Y, Zhang L, Li P, Cui X, Chen L, et al. Expression and prognostic role of Spy1 as a novel cell cycle protein in hepatocellular carcinoma. Exp Mol Pathol 2009; 87:167-72; PMID:19686732; http://dx.doi.org/10.1016/j.yexmp.2009.07.011
   PubMed Web of Science ®Google Scholar
• Hang Q, Fei M, Hou S, Ni Q, Lu C, Zhang G, Gong P, Guan C, Huang X, He S. Expression of Spy1 protein in human Non-Hodgkin's Lymphomas is correlated with phosphorylation of p27(Kip1) on Thr187 and cell proliferation. Med Oncol 2012; PMID:22492278
   PubMed Web of Science ®Google Scholar
• Zhang L, Shen A, Ke Q, Zhao W, Yan M, Cheng C. Spy1 is frequently overexpressed in malignant gliomas and critically regulates the proliferation of glioma cells. J Mol Neurosci 2012; 47:485-94; PMID:22447439; http://dx.doi.org/10.1007/s12031-012-9709-5
   PubMed Web of Science ®Google Scholar
• Slingerland J, Pagano M. Regulation of the cdk inhibitor p27 and its deregulation in cancer. J Cell Physiol 2000; 183:10-17; PMID:10699961; http://dx.doi.org/10.1002/(SICI)1097-4652(200004)183:110AID-JCP23.0.CO;2-I
   PubMed Web of Science ®Google Scholar
• Corsino P, Davis B, Law M, Chytil A, Forrester E, Nørgaard P, Teoh N, Law B. Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression. Cancer Res 2007; 67:3135-44; PMID:17409420; http://dx.doi.org/10.1158/0008-5472.CAN-06-3815
   PubMed Web of Science ®Google Scholar
• Vlach J, Hennecke S, Amati B. Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27. Embo J 1997; 16:5334-44; PMID:9311993; http://dx.doi.org/10.1093/emboj/16.17.5334
   PubMed Web of Science ®Google Scholar